ChemoMetec A/S
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, an… Read more
Market Cap & Net Worth: ChemoMetec A/S (CHEMM)
ChemoMetec A/S (CO:CHEMM) has a market capitalization of $988.71 Million (Dkr7.18 Billion) as of March 18, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #7531 globally and #13 in its home market, demonstrating a -0.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ChemoMetec A/S's stock price Dkr412.80 by its total outstanding shares 17402479 (17.40 Million).
ChemoMetec A/S Market Cap History: 2015 to 2026
ChemoMetec A/S's market capitalization history from 2015 to 2026. Data shows growth from $87.45 Million to $988.71 Million (33.78% CAGR).
ChemoMetec A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ChemoMetec A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.32x
ChemoMetec A/S's market cap is 3.32 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
8.83x
ChemoMetec A/S's market cap is 8.83 times its annual earnings
1.95x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $78.59 Million | $85.23 Million | $10.48 Million | 0.92x | 7.50x |
| 2017 | $59.74 Million | $90.33 Million | $7.49 Million | 0.66x | 7.98x |
| 2018 | $194.89 Million | $112.69 Million | $18.21 Million | 1.73x | 10.70x |
| 2019 | $491.00 Million | $175.51 Million | $41.84 Million | 2.80x | 11.73x |
| 2020 | $1.38 Billion | $214.10 Million | $59.16 Million | 6.47x | 23.40x |
| 2021 | $2.00 Billion | $281.13 Million | $88.35 Million | 7.10x | 22.58x |
| 2022 | $1.65 Billion | $428.39 Million | $159.47 Million | 3.86x | 10.37x |
| 2023 | $929.31 Million | $444.40 Million | $178.67 Million | 2.09x | 5.20x |
| 2024 | $1.16 Billion | $407.87 Million | $136.28 Million | 2.86x | 8.54x |
| 2025 | $1.65 Billion | $495.57 Million | $186.41 Million | 3.32x | 8.83x |
Competitor Companies of CHEMM by Market Capitalization
Companies near ChemoMetec A/S in the global market cap rankings as of March 18, 2026.
Key companies related to ChemoMetec A/S by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
ChemoMetec A/S Historical Marketcap From 2015 to 2026
Between 2015 and today, ChemoMetec A/S's market cap moved from $87.45 Million to $ 988.71 Million, with a yearly change of 33.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr988.71 Million | -39.96% |
| 2025 | Dkr1.65 Billion | +41.40% |
| 2024 | Dkr1.16 Billion | +25.31% |
| 2023 | Dkr929.31 Million | -43.81% |
| 2022 | Dkr1.65 Billion | -17.11% |
| 2021 | Dkr2.00 Billion | +44.12% |
| 2020 | Dkr1.38 Billion | +181.95% |
| 2019 | Dkr491.00 Million | +151.94% |
| 2018 | Dkr194.89 Million | +226.24% |
| 2017 | Dkr59.74 Million | -23.99% |
| 2016 | Dkr78.59 Million | -10.13% |
| 2015 | Dkr87.45 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ChemoMetec A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $988.71 Million USD |
| MoneyControl | $988.71 Million USD |
| MarketWatch | $988.71 Million USD |
| marketcap.company | $988.71 Million USD |
| Reuters | $988.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.